Neumora Therapeutics (NMRA) Q4 2025 earnings review
Pipeline Mixed Bag: NMRA-511 Shines While Obesity Asset Stumbles
Neumora closed 2025 with disciplined cash management and mixed clinical updates. Net loss remained Stable at $59.4M in Q4, aided by Decelerating R&D expenses as the KOASTAL-1 trial costs rolled off. The clinical narrative is sharply divided: NMRA-511 delivered compelling efficacy signals in Alzheimer's agitation, and pivotal Navacaprant MDD trials achieved full enrollment. However, the highly anticipated obesity candidate, NMRA-215, suffered a major setback due to rat toxicology findings, delaying clinic entry by a full year to Q1 2027. With Navacaprant data consolidated to a joint Q2 2026 readout, the catalyst calendar is thinning, though the $182.5M cash balance secures the runway into Q3 2027.
🐂 Bull Case
In a pre-specified population (NPI-AA ≥4), NMRA-511 demonstrated a Cohen's d effect size of 0.34 on total CMAI and 0.51 on aggression. This is an unsurpassed clinical effect comparable to pivotal studies of approved drugs, significantly de-risking the upcoming Phase 2 trial.
KOASTAL-2 and -3 are fully enrolled with over 400 patients each. The implementation of stricter screening measures (SAFER) appears to have been executed without crippling enrollment timelines.
🐻 Bear Case
NMRA-215 hit a massive speed bump. Unexpected adverse findings in 5 of 142 rats during a 13-week toxicology study have forced a repeat study, delaying clinic entry from Q1 2026 to Q1 2027 and forfeiting early-mover advantage in the obesity space.
Management previously guided to sequential readouts (KOASTAL-3 in Q1 2026, KOASTAL-2 in Q2 2026). Consolidating these into a joint Q2 2026 readout creates a concentrated, high-stakes binary event that delays the earliest possible catalyst.
⚖️ Verdict: ⚪
Neutral. Stable cash burn and the positive NMRA-511 data are encouraging, but the 12-month delay to the NMRA-215 obesity program is a severe blow to the pipeline's optionality. The company's valuation now rests heavily on the Q2 2026 Navacaprant joint readout.
Key Themes
NMRA-215 Toxicology Setback Contradicts Positive Efficacy Narrative
Despite management touting positive 12-week diet-induced obesity (DIO) mouse data showing semaglutide-like weight loss, this narrative is completely undermined by the 13-week rat toxicology study. Unexpected adverse findings in 5 of 142 animals triggered a for-cause audit and a complete study repeat with a new CRO. This Decelerating pipeline timeline pushes Phase 1 initiation from Q1 2026 to Q1 2027, meaning Neumora will be burning cash for another year before securing human proof-of-concept in a fiercely competitive market.
NMRA-511 Shows Unsurpassed Effect Size in AD Agitation
The Phase 1b pre-specified analysis for NMRA-511 yielded strong results in patients with NPI-AA scores ≥4 (aligning with pivotal study norms). The Cohen's d effect sizes of 0.34 (CMAI total) and 0.51 (CMAI aggression) are highly competitive against current standards like Rexulti and Auvelity. This Accelerating catalyst sets up a strong foundation for the Phase 2 study scheduled for Q1 2027.
NMRA-898 Selected as Lead M4 PAM
After nearly a year of clinical hold ambiguity regarding the older 266 compound, Neumora has officially pivoted, designating NMRA-898 as its M4 franchise lead. Early Phase 1 data validates the target with exposure-dependent heart rate increases (similar to KarXT) and an 80-100 hour half-life, which Reverses previous franchise stagnation and supports highly desirable once-daily dosing.
Consolidation of Navacaprant Readouts
The pivotal KOASTAL-2 and KOASTAL-3 studies for Navacaprant are fully enrolled (>400 patients each). However, management shifted the readout timeline from staggered (Q1 and Q2 2026) to a joint readout in Q2 2026. This Decelerating timeline creates a massive binary overhang for Q2 2026, removing the opportunity for an earlier Q1 de-risking event.
Disciplined Expense Management
R&D spending is Decelerating. FY25 R&D dropped to $176.1M from $200.9M in FY24, primarily due to the completion of KOASTAL-1 and reduced Amgen collaboration expenses. This discipline is essential given the pipeline delays, helping stretch the $182.5M cash balance.
Other KPIs
Stable compared to $45.9 million in Q4 2024. The slight decrease reflects the roll-off of costs associated with the failed KOASTAL-1 study, partially offset by increased preclinical and manufacturing spend as earlier-stage assets like NMRA-898 advance.
Decelerating balance, down from $307.6 million at the end of 2024. The $125 million burn over the year demonstrates efficient capital allocation, aligning with the company's projection that this balance will fund operations into Q3 2027.
Stable to slightly down compared to $62.5 million in FY 2024. The decrease was driven by reduced consulting and personnel-related costs, further evidence of tightening operational efficiency in the wake of the KOASTAL-1 failure.
Guidance
Accelerating/Improving. Prior guidance indicated funding 'into 2027'. Specifying the third quarter of 2027 provides slightly more breathing room past the crucial Q2 2026 Navacaprant readouts, though the NMRA-215 delay means capital will likely need to be raised before that specific asset yields clinical proof-of-concept.
Decelerating. Previously, KOASTAL-3 was guided for Q1 2026 and KOASTAL-2 for Q2 2026. Consolidating both into Q2 2026 pushes the earliest catalyst back by a quarter.
Decelerating. A major delay from the previously guided Q1 2026 start. The requirement to repeat the 13-week rat toxicology study essentially stalls the program for a full year.
Key Questions
Nature of NMRA-215 Toxicology Findings
What exactly were the unexpected adverse findings observed in the 5 rats during the 13-week toxicology study, and what specific factors lead management to believe this was a 'study conduct issue' rather than an on-target toxicity?
Rationale for Joint KOASTAL Readout
With KOASTAL-2 and -3 fully enrolled, what drove the decision to consolidate the top-line readouts into a joint announcement in Q2 2026 rather than releasing KOASTAL-3 in Q1 as previously planned?
NMRA-898 Cardiovascular Profile
You noted exposure-dependent increases in heart rate for NMRA-898 similar to Cobenfy. How does the company plan to manage or differentiate this cardiovascular profile clinically, especially compared to competitors targeting the M4 receptor without peripheral anticholinergic additions?
NMRA-511 Phase 2 Design
Given the robust effect sizes seen in the pre-specified NPI-AA ≥4 population for NMRA-511, will this specific cutoff be utilized as a primary inclusion criterion for the Phase 2 study initiating in Q1 2027?